MissionIR Articles

Cutaneous T-cell lymphoma, or CTCL, is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages. A recent article discussed Soligenix’s (NASDAQ: SNGX) efforts to develop therapies aimed at addressing critical gaps in rare disease treatment, including CTCL.  The publication reads, “Within a challenging diagnostic and treatment landscape, Soligenix is advancing a novel therapeutic…